<DOC>
	<DOCNO>NCT02646670</DOCNO>
	<brief_summary>The purpose study compare efficacy treatment diabetic macular edema ( DME ) use Ranibizumab ( Lucenti® ) , Aflibercept ( Eylea® ) Aflibercept ( Eylea® ) plus Ranibizumab ( Lucentis® ) . It randomize clinical trial evaluate efficacy combination two substance currently use treatment DME . Will allocate different four group randomly pacients receive treatment intravitreal injection ranibizumab , aflibercept combination aflibercept ranibizumab .</brief_summary>
	<brief_title>Efficacy Ranibizumab Therapy With Aflibercept Patients With Diabetic Macular Edema</brief_title>
	<detailed_description>Interventions carry intravitreal injection patient formal indication diabetic macular edema treatment previously assess complete eye examination Goiania Eye Institute ( Instituto de Olhos de Goiânia ) Patients divide four group : - In first group hold three application intravitreal ranibizumab 0.1 ml , one application every month follow Optical Coherence Tomography day 1 , 3 , 5 , 10 30 follow application . - In second group hold three application Intravitreal Aflibercept 0.1 ml , one application month follow monitoring Optical Coherence Tomography day 1 , 3 , 5 , 10 30 subsequent - The third group hold two application Ranibizumab 0.1 ml intersperse one application Aflibercept 0.1 ml second month subsequent evaluation Optical Coherence Tomography day 1 , 3 , 5 , 10 30 . - In fourth group hold two application 0.1 ml Aflibercept intersperse one application Ranibizumab 0.1 ml second month subsequent evaluation Optical Coherence Tomography day 1 , 3 , 5 , 10 30 .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>patient Diabetic macular edema patient without diabetic macular edema , diabetic macular edema disease make confuse diagnose</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>diabetic macular edema</keyword>
	<keyword>aflibercept</keyword>
	<keyword>ranibizumab</keyword>
</DOC>